Novel Pharmaceutical Approaches to Reflux Disease

Gastroenterology Clinics of North America

Volumn 42, Issue 1, 2013, Pages 93-117

  Dutta, Usha ^a   Armstrong, David ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Gastroesophageal reflux; Novel therapies; Pathophysiology; Proton pump inhibitors; TLESR

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; BENATOPRAZOLE; CANNABINOID RECEPTOR AGONIST; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DEXRABEPRAZOLE; ESOMEPRAZOLE; GLUTAMATE RECEPTOR ANTAGONIST; HERBACEOUS AGENT; ILAPRAZOLE; IMIDAZOPYRIDINE DERIVATIVE; LANSOPRAZOLE; LINAPRAZAN; MACROLIDE; METABOTROPIC RECEPTOR ANTAGONIST; OMEPRAZOLE; PANTOPRAZOLE; PEPSIN A; POTASSIUM COMPETITIVE ACID BLOCKER; PROBIOTIC AGENT; PROKINETIC AGENT; PROTON PUMP INHIBITOR; PYRIMIDINE DERIVATIVE; RABEPRAZOLE; REVAPRAZAN; RIKKUNSHITO; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SORAPRAZAN; UNCLASSIFIED DRUG;

ABDOMINAL DISEASE; DIGESTIVE SYSTEM DISEASE; DISEASE CONTROL; DRUG METABOLISM; DUODENOGASTROESOPHAGEAL REFLUX; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL MOTILITY; HEALING; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PREVALENCE; REVIEW; STOMACH ACID; STOMACH DISTENSION; STOMACH EMPTYING; SYMPTOM; TREATMENT RESPONSE; UPPER GASTROINTESTINAL TRACT;

ALGINATES; BACLOFEN; DRUG THERAPY, COMBINATION; GABA-B RECEPTOR AGONISTS; GASTROESOPHAGEAL REFLUX; GLUCURONIC ACID; HEXURONIC ACIDS; HISTAMINE H2 ANTAGONISTS; HUMANS; PROTON PUMP INHIBITORS;

EID: 84875333448     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2012.12.001     Document Type: Review

References (84)

1. Vakil N., van Zanten S.V., Kahrilas P., et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006, 101:1900-1920.
2. Sandler R.S., Everhart J.E., Donowitz M., et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002, 122:1500-1511.
3. Peery A.F., Dellon E.S., Lund J., et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012, 143:1179-1187.
4. Dent J., El-Serag H.B., Wallander M.A., et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005, 54:710-717.
5. Kahrilas P.J., Shaheen N.J., Vaezi M.F. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008, 135:1392-1413.
6. Fass R., Shapiro M., Dekel R., et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next?. Aliment Pharmacol Ther 2005, 22:79-94.
7. Altan E., Blondeau K., Pauwels A., et al. Evolving pharmacological approaches in gastroesophageal reflux disease. Expert Opin Emerg Drugs 2012, 17:347-359.
8. Raghunath A.S., Hungin A.P., Mason J., et al. Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors. Aliment Pharmacol Ther 2009, 29:431-439.
9. Pandolfino J.E., Shi G., Trueworthy B., et al. Esophagogastric junction opening during relaxation distinguishes nonhernia reflux patients, hernia patients, and normal subjects. Gastroenterology 2003, 125:1018-1024.
10. Hirschowitz B.I. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991, 101:1149-1158.
11. Herbella F.A., Vicentine F.P., Silva L.C., et al. Postprandial proximal gastric acid pocket and gastroesophageal reflux disease. Dis Esophagus 2012, 25:652-655.
12. Kwiatek M.A., Roman S., Fareeduddin A., et al. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients. Aliment Pharmacol Ther 2011, 34:59-66.
13. Buckles D.C., Sarosiek I., McMillin C., et al. Delayed gastric emptying in gastroesophageal reflux disease: reassessment with new methods and symptomatic correlations. Am J Med Sci 2004, 327:1-4.
14. Vaezi M.F., Richter J.E. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996, 111:1192-1199.
15. Araki Y., Mukaisho K.I., Fujiyama Y., et al. The herbal medicine rikkunshito exhibits strong and differential adsorption properties for bile salts. Exp Ther Med 2012, 3:645-649.
16. Blackshaw L.A., Staunton E., Lehmann A., et al. Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol 1999, 277:G867-G874.
17. Keywood C., Wakefield M., Tack J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009, 58:1192-1199.
18. Beaumont H., Jensen J., Carlsson A., et al. Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol 2009, 156:153-162.
19. Rohof W.O., Aronica E., Beaumont H., et al. Localization of mGluR5, GABAB, GABAA, and cannabinoid receptors on the vago-vagal reflex pathway responsible for transient lower esophageal sphincter relaxation in humans: an immunohistochemical study. Neurogastroenterol Motil 2012, 24:383-392.
20. Hirsch D.P., Tiel-Van Buul M.M., Tytgat G.N., et al. Effect of L-NMMA on postprandial transient lower esophageal sphincter relaxations in healthy volunteers. Dig Dis Sci 2000, 45:2069-2075.
21. Boeckxstaens G.E., Hirsch D.P., Fakhry N., et al. Involvement of cholecystokininA receptors in transient lower esophageal sphincter relaxations triggered by gastric distension. Am J Gastroenterol 1998, 93:1823-1828.
22. Sifrim D., Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 2012, 61:1340-1354.
23. Boeckxstaens G.E. Alterations confined to the gastro-oesophageal junction: the relationship between low LOSP, TLOSRs, hiatus hernia and acid pocket. Best Pract Res Clin Gastroenterol 2010, 24:821-829.
24. Yang L., Francois F., Pei Z. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res 2012, 18:2138-2144.
25. Indrio F., Riezzo G., Raimondi F., et al. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur J Clin Invest 2011, 41:417-422.
26. Hsu Y.C., Lin H.J. Addition of prokinetic therapy to a PPI in reflux diseases. Aliment Pharmacol Ther 2011, 33:983-985.
27. Kim Y.S., Kim T.H., Choi C.S., et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol 2005, 11:4210-4214.
28. Tobey N.A., Carson J.L., Alkiek R.A., et al. Dilated intercellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. Gastroenterology 1996, 111:1200-1205.
29. Tobey N.A., Hosseini S.S., Argote C.M., et al. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am J Gastroenterol 2004, 99:13-22.
30. Chu C.L., Zhen Y.B., Lv G.P., et al. Microalterations of esophagus in patients with non-erosive reflux disease: in-vivo diagnosis by confocal laser endomicroscopy and its relationship with gastroesophageal reflux. Am J Gastroenterol 2012, 107:864-874.
31. Knowles C.H., Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut 2008, 57:674-683.
32. Farre R., De V.R., Geboes K., et al. Critical role of stress in increased oesophageal mucosa permeability and dilated intercellular spaces. Gut 2007, 56:1191-1197.
33. Sharma P., Shaheen N.J., Perez M.C., et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies. Aliment Pharmacol Ther 2009, 29:731-741.
34. Kahrilas P.J., Falk G.W., Johnson D.A., et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000, 14:1249-1258.
35. Gralnek I.M., Dulai G.S., Fennerty M.B., et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 2006, 4:1452-1458.
36. Edwards S.J., Lind T., Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 2006, 24:743-750.
37. Laine L., Katz P.O., Johnson D.A., et al. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies. Aliment Pharmacol Ther 2011, 33:203-212.
38. Hunt R.H., Armstrong D., Yaghoobi M., et al. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008, 28:187-199.
39. Hunt R.H., Armstrong D., Yaghoobi M., et al. The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. Aliment Pharmacol Ther 2010, 31:648-657.
40. Scarpignato C., Hunt R.H. Proton pump inhibitors: the beginning of the end or the end of the beginning?. Curr Opin Pharmacol 2008, 8:677-684.
41. Wang L., Zhou L., Hu H., et al. Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial. Curr Med Res Opin 2012, 28:101-109.
42. Rosemary J., Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2007, 2:93-109.
43. Li X.Q., Andersson T.B., Ahlstrom M., et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004, 32:821-827.
44. Chowers Y., Atarot T., Kostadinov A., et al. PPI activity is optimized by VB101, a parietal cell activator. Gastroenterology 2008, 134(Suppl 1):A-172.
45. Sorba G., Galli U., Cena C., et al. A new furoxan NO-donor rabeprazole derivative and related compounds. Chembiochem 2003, 4:899-903.
46. Saha J.K., Wang T., Stewart R., et al. Enhanced gastroprotective and anti-ulcerogenic activities in rats of a new class of proton pump inhibitor containing nitrosothiol nitric oxide donor. Gastroenterology 2001, 120(Suppl 1):A144-A145.
47. Rackoff A., Agrawal A., Hila A., et al. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 2005, 18:370-373.
48. Pouchain D., Bigard M.A., Liard F., et al. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. BMC Gastroenterol 2012, 23:12-18.
49. Manabe N., Haruma K., Ito M., et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus 2012, 25:373-380.
50. Madan K., Ahuja V., Kashyap P.C., et al. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus 2004, 17:274-278.
51. Cho Y.K., Choi M.G., Park E.Y., et al. Effect of mosapride combined with esomeprazole improves esophageal peristaltic function in patients with gastroesophageal reflux disease: a study using high resolution manometry. Dig Dis Sci 2012, [Epub ahead of print].
52. Ezzat W.F., Fawaz S.A., Fathey H., et al. Virtue of adding prokinetics to proton pump inhibitors in the treatment of laryngopharyngeal reflux disease: prospective study. J Otolaryngol Head Neck Surg 2011, 40:350-356.
53. Futagami S., Iwakiri K., Shindo T., et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol 2010, 45:413-421.
54. Miwa H., Inoue K., Ashida K., et al. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011, 33:323-332.
55. Miyamoto M., Manabe N., Haruma K. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy. Intern Med 2010, 49:1469-1476.
56. Karamanolis G., Vanuytsel T., Sifrim D., et al. Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008, 53:2387-2393.
57. Dent J. Reflux inhibitor drugs: an emerging novel therapy for gastroesophageal reflux disease. J Dig Dis 2010, 11:72-75.
58. Zhang Q., Lehmann A., Rigda R., et al. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002, 50:19-24.
59. Gerson L.B., Huff F.J., Hila A., et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2010, 105:1266-1275.
60. Boeckxstaens G.E., Rydholm H., Lei A., et al. Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects. Aliment Pharmacol Ther 2010, 31:1208-1217.
61. Boeckxstaens G.E., Beaumont H., Hatlebakk J.G., et al. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut 2011, 60:1182-1188.
62. Beaumont H., Smout A., Aanen M., et al. The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study. Aliment Pharmacol Ther 2009, 30:937-946.
63. Froestl W. Chemistry and pharmacology of GABAB receptor ligands. Adv Pharmacol 2010, 58:19-62.
64. Vakil N.B., Huff F.J., Bian A., et al. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2011, 106:1427-1438.
65. Lehmann A., Jensen J.M., Boeckxstaens G.E. GABAB receptor agonism as a novel therapeutic modality in the treatment of gastroesophageal reflux disease. Adv Pharmacol 2010, 58:287-313.
66. Zerbib F., Keywood C., Strabach G. Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH-impedance study in healthy subjects. Neurogastroenterol Motil 2010, 22:859-865.
67. Rohof W.O., Lei A., Hirsch D.P., et al. The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Aliment Pharmacol Ther 2012, 35:1231-1242.
68. Scarpellini E., Blondeau K., Boecxstaens V., et al. Effect of rimonabant on oesophageal motor function in man. Aliment Pharmacol Ther 2011, 33:730-737.
69. Fass R. Healing erosive esophagitis with a proton pump inhibitor: the more the merrier?. Am J Gastroenterol 2012, 107:531-533.
70. Hershcovici T., Fass R. Pharmacological management of GERD: where does it stand now?. Trends Pharmacol Sci 2011, 32:258-264.
71. Curran M.P., Robinson D.M. Mosapride in gastrointestinal disorders. Drugs 2008, 68:981-991.
72. Scarpellini E., Vos R., Blondeau K., et al. The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man. Aliment Pharmacol Ther 2011, 33:99-105.
73. Fass R. Therapeutic options for refractory gastroesophageal reflux disease. J Gastroenterol Hepatol 2012, 27(Suppl 3):3-7.
74. Koutsoumbi P., Epanomeritakis E., Tsiaoussis J., et al. The effect of erythromycin on human esophageal motility is mediated by serotonin receptors. Am J Gastroenterol 2000, 95:3388-3392.
75. Rohof W.O., Bennink R.J., de Ruigh A.A., et al. Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period. Gut 2012, 61:1670-1677.
76. Ozaki K., Monnai M., Onoma M., et al. Effects of mitemcinal (GM-611), an orally active erythromycin-derived prokinetic agent, on delayed gastric emptying and postprandial glucose in a new minipig model of diabetes. J Diabetes Complications 2008, 22:339-347.
77. Takanashi H., Cynshi O. Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis. Regul Pept 2009, 155:18-23.
78. Tominaga K., Iwakiri R., Fujimoto K., et al. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan. J Gastroenterol 2012, 47:284-292.
79. Bai Y., Xu M.J., Yang X., et al. A systematic review on intrapyloric botulinum toxin injection for gastroparesis. Digestion 2010, 81:27-34.
80. Zerbib F., Simon M. Novel therapeutics for gastro-esophageal reflux symptoms. Expert Rev Clin Pharmacol 2012, 5:533-541.
81. Krarup A.L., Ny L., Astrand M., et al. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol Ther 2011, 33:1113-1122.
82. Simon B., Ravelli G.P., Goffin H. Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1996, 10:441-446.
83. Fass R. Alternative therapeutic approaches to chronic proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2012, 10:338-340.
84. Adachi K., Furuta K., Miwa H., et al. A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease. Dig Dis Sci 2012, 57:1609-1617.